Adding Triptorelin to Breast CA Chemo May Up Ovarian Recovery

This article originally appeared here.
Adding Triptorelin to Breast CA Chemo May Up Ovarian Recovery
Adding Triptorelin to Breast CA Chemo May Up Ovarian Recovery

HealthDay News — For premenopausal women with breast cancer, chemotherapy plus the luteinizing hormone-releasing hormone analogue (LHRHa) triptorelin is associated with higher long-term probability of ovarian function recovery, according to a study published in the Dec. 22/29 issue of the Journal of the American Medical Association.

Matteo Lambertini, MD, from the Istituto Nazionale per la Ricerca sul Cancro in Genova, Italy, and colleagues examined the long-term results of LHRHa-induced ovarian suppression during breast cancer chemotherapy. Two hundred eighty-one premenopausal women with stage I to III hormone-receptor positive or hormone-receptor negative breast cancer were enrolled and randomized to chemotherapy plus LHRHa (148 patients) or chemotherapy alone (control; 133 patients). Participants were followed for a median of 7.3 years.

The researchers found that the five-year cumulative incidence estimate of menstrual resumption was 72.6% in the LHRHa group and 64.0% in the control group (hazard ratio [HR], 1.28; 95% confidence interval [CI], 0.98 to 1.68; P=0.07; age-adjusted HR, 1.48; 95% CI, 1.12 to 1.95; P=0.006). The five-year cumulative incidence of pregnancy was 2.1 and 1.6% in the LHRHa and control groups, respectively (HR, 2.56; 95% CI, 0.68 to 9.60; P=0.14; age-adjusted HR, 2.40; 95%  CI, 0.62 to 9.22; P=0.20).

"Concurrent administration of triptorelin and chemotherapy, compared with chemotherapy alone, was associated with higher long-term probability of ovarian function recovery, without a statistically significant difference in pregnancy rate," the authors write.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Loading links....